-
公开(公告)号:US09156830B2
公开(公告)日:2015-10-13
申请号:US14118113
申请日:2012-05-16
申请人: Noriyuki Kurose , Yasuyoshi Iso , Naoko Yamaguchi , Bin Shao , Laykea Tafesse , Xiaoming Zhou , Jianming Yu
发明人: Noriyuki Kurose , Yasuyoshi Iso , Naoko Yamaguchi , Bin Shao , Laykea Tafesse , Xiaoming Zhou , Jianming Yu
IPC分类号: A61K31/497 , C07D413/14 , C07D401/14 , C07D401/04 , C07D413/04 , C07D413/12 , C07D417/14 , C07D271/10 , C07D271/06 , C07D405/14
CPC分类号: C07D413/14 , C07D271/06 , C07D271/10 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/12 , C07D417/14
摘要: The invention relates to compounds of Formula I: wherein Ar1, Ar2, Ar3, L1, L2, Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.
摘要翻译: 本发明涉及式I化合物:其中Ar1,Ar2,Ar3,L1,L2,Y,Z和v在本说明书中定义,及其药学上可接受的衍生物,包含有效量的式I化合物或 药物可接受的衍生物,以及治疗或预防诸如疼痛,UI,溃疡,IBD和IBS的病症的方法,包括向有需要的动物施用有效量的式I化合物或其药学上可接受的衍生物。
-
公开(公告)号:US20130303526A1
公开(公告)日:2013-11-14
申请号:US13821732
申请日:2011-09-16
申请人: Chiyou NI , Bin Shao , Laykea Tafesse , Jiangchao Yao , Jianming Yu , Xiaoming Zhou
发明人: Chiyou NI , Bin Shao , Laykea Tafesse , Jiangchao Yao , Jianming Yu , Xiaoming Zhou
IPC分类号: C07D213/30 , C07D213/81 , C07D213/58 , C07D213/643 , C07D401/12 , C07D401/04 , C07D401/14
CPC分类号: C07D213/81 , C07D213/30 , C07D213/46 , C07D213/50 , C07D213/57 , C07D213/58 , C07D213/643 , C07D213/65 , C07D213/74 , C07D213/79 , C07D213/84 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
摘要: The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
摘要翻译: 本发明涉及式(I)的取代吡啶化合物及其药学上可接受的盐,前体药物和溶剂合物,其中R1a,A1,A2,E,G,Z1和Z2如本说明书所述定义。 本发明还涉及式I化合物用于治疗对钠通道阻断有反应的病症。 本发明的化合物特别适用于治疗疼痛。
-
公开(公告)号:US09056832B2
公开(公告)日:2015-06-16
申请号:US13821732
申请日:2011-09-16
申请人: Chiyou Ni , Bin Shao , Laykea Tafesse , Jiangchao Yao , Jianming Yu , Xiaoming Zhou
发明人: Chiyou Ni , Bin Shao , Laykea Tafesse , Jiangchao Yao , Jianming Yu , Xiaoming Zhou
IPC分类号: C07D401/04 , C07D213/81 , C07D213/30 , C07D401/12 , C07D213/58 , C07D213/643 , C07D401/14 , C07D213/79 , C07D213/74 , A61K31/444 , A61K31/4418 , A61P23/00 , C07D213/46 , C07D213/84 , C07D403/14
CPC分类号: C07D213/81 , C07D213/30 , C07D213/46 , C07D213/50 , C07D213/57 , C07D213/58 , C07D213/643 , C07D213/65 , C07D213/74 , C07D213/79 , C07D213/84 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14
摘要: The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, A1, A2, E, G, Z1, and Z2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
摘要翻译: 本发明涉及式(I)的取代吡啶化合物及其药学上可接受的盐,前体药物和溶剂合物,其中R1a,A1,A2,E,G,Z1和Z2如本说明书所述定义。 本发明还涉及式I化合物用于治疗对钠通道阻断有反应的病症。 本发明的化合物特别适用于治疗疼痛。
-
公开(公告)号:US09656959B2
公开(公告)日:2017-05-23
申请号:US13996082
申请日:2011-12-21
申请人: Chiyou Ni , Minnie Park , Bin Shao , Laykea Tafesse , Jiangchao Yao , Mark A. Youngman , Xiaoming Zhou
发明人: Chiyou Ni , Minnie Park , Bin Shao , Laykea Tafesse , Jiangchao Yao , Mark A. Youngman , Xiaoming Zhou
IPC分类号: C07D213/75 , C07D401/02 , C07D401/12 , C07D401/14 , C07D213/76 , C07D213/81 , C07D413/12
CPC分类号: C07D213/75 , C07D213/76 , C07D213/81 , C07D401/02 , C07D401/12 , C07D401/14 , C07D413/12
摘要: The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, R1b, R2a, R2b, R2c, A1, A2, and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
-
公开(公告)号:US20140005212A1
公开(公告)日:2014-01-02
申请号:US13996082
申请日:2011-12-21
申请人: Chiyou Ni , Minnie Park , Bin Shao , Laykea Tafesse , Jiangchao Yao , Mark Youngman , Xiaoming Zhou
发明人: Chiyou Ni , Minnie Park , Bin Shao , Laykea Tafesse , Jiangchao Yao , Mark Youngman , Xiaoming Zhou
IPC分类号: C07D213/75 , C07D413/12 , C07D401/12 , C07D401/14 , C07D213/81 , C07D213/76
CPC分类号: C07D213/75 , C07D213/76 , C07D213/81 , C07D401/02 , C07D401/12 , C07D401/14 , C07D413/12
摘要: The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R1a, R1b, R2a, R2b, R2c, A1, A2, and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
摘要翻译: 本发明涉及式I的取代的吡啶化合物:(I)及其药学上可接受的盐,前药和溶剂化物,其中R1a,R1b,R2a,R2b,R2c,A1,A2和X定义如 规范。 本发明还涉及式I化合物用于治疗对钠通道阻断有反应的病症。 本发明的化合物特别适用于治疗疼痛。
-
公开(公告)号:US09598447B2
公开(公告)日:2017-03-21
申请号:US13996440
申请日:2011-12-21
申请人: Dawit Tadesse , Laykea Tafesse , Xiaoming Zhou
发明人: Dawit Tadesse , Laykea Tafesse , Xiaoming Zhou
IPC分类号: C07F9/6561 , C07F9/6558
CPC分类号: C07F9/6561 , C07F9/65583
摘要: The disclosure relates to Phosphorus-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the dashed line, A, B, Q, R1, R2, R3, R4, Y1, Z, and a are as defined herein, compositions comprising an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Phosphorus-Substituted Quinoxaline-Type Piperidine Compound.
-
公开(公告)号:US20110281885A1
公开(公告)日:2011-11-17
申请号:US12879885
申请日:2010-09-10
申请人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
发明人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
IPC分类号: A61K31/496 , A61K31/497 , C12N5/07 , C07D417/04 , C07D401/04 , A61P25/00
CPC分类号: C07D213/74 , C07D213/85 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/06 , C07D333/16
摘要: A compound of formula: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.
摘要翻译: 本文公开的其中A,Ar,R 3,R 6和m的化合物或其药学上可接受的盐(“氰基亚氨基哌嗪化合物”),包含有效量的氰基亚氨基哌嗪化合物的组合物,以及治疗或预防的方法 疼痛,尿失禁,溃疡,炎性肠病,肠易激综合征,成瘾性疾病,帕金森病,帕金森综合征,焦虑症,癫痫,中风,癫痫发作,瘙痒症状,精神病,认知障碍,记忆缺陷, 限制性脑功能,亨廷顿氏舞蹈病,肌萎缩性侧索硬化,痴呆,视网膜病变,肌肉痉挛,偏头痛,呕吐,运动障碍或抑郁症,包括向有需要的动物施用有效量的氰基亚氨基哌嗪化合物。
-
公开(公告)号:US07279493B2
公开(公告)日:2007-10-09
申请号:US10607563
申请日:2003-06-27
申请人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
发明人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
IPC分类号: C07D277/04 , A61K43/80
CPC分类号: C07D213/74 , C07D213/85 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/06 , C07D333/16
摘要: A compound of formula: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.
摘要翻译: 式中的化合物:其中A,Ar,R 3,R 6和m在本文中公开,或其药学上可接受的盐(“氰基亚氨基哌嗪化合物”), 包含有效量的氰基亚氨基哌嗪化合物的组合物,治疗或预防疼痛,尿失禁,溃疡,炎性肠病,肠易激综合征,成瘾性疾病,帕金森病,帕金森综合征,焦虑症,癫痫,中风, 包括给予一个或多个癫痫发作,瘙痒症状,精神病,认知障碍,记忆缺陷,限制性脑功能,亨廷顿氏舞蹈病,肌萎缩性侧索硬化,痴呆,视网膜病变,肌肉痉挛,偏头痛,呕吐,运动障碍或抑郁症 公开了有效量的氰酰亚胺哌嗪化合物的需要动物。
-
公开(公告)号:US07799786B2
公开(公告)日:2010-09-21
申请号:US11899379
申请日:2007-09-04
申请人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
发明人: Donald J. Kyle , Qun Sun , Laykea Tafesse , Chongwu Zhang , Xiaoming Zhou
IPC分类号: C07D237/00 , C07D241/00 , A61K31/50 , A61K31/497
CPC分类号: C07D213/74 , C07D213/85 , C07D237/20 , C07D239/42 , C07D241/20 , C07D285/06 , C07D333/16
摘要: A compound of formula: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Cyanoiminopiperazine Compound are disclosed.
摘要翻译: 本文公开的其中A,Ar,R 3,R 6和m的化合物或其药学上可接受的盐(“氰基亚氨基哌嗪化合物”),包含有效量的氰基亚氨基哌嗪化合物的组合物,以及治疗或预防的方法 疼痛,尿失禁,溃疡,炎性肠病,肠易激综合征,成瘾性疾病,帕金森病,帕金森综合征,焦虑症,癫痫,中风,癫痫发作,瘙痒症状,精神病,认知障碍,记忆缺陷, 限制性脑功能,亨廷顿氏舞蹈病,肌萎缩性侧索硬化,痴呆,视网膜病变,肌肉痉挛,偏头痛,呕吐,运动障碍或抑郁症,包括向有需要的动物施用有效量的氰基亚氨基哌嗪化合物。
-
公开(公告)号:US06864261B2
公开(公告)日:2005-03-08
申请号:US10429078
申请日:2003-05-02
申请人: Parviz Gharagozloo , Khondaker Islam , Donald J. Kyle , Qun Sun , Laykea Tafesse , John William Frank Whitehead , Ji Yang , Xiaoming Zhou
发明人: Parviz Gharagozloo , Khondaker Islam , Donald J. Kyle , Qun Sun , Laykea Tafesse , John William Frank Whitehead , Ji Yang , Xiaoming Zhou
IPC分类号: A61P25/00 , A61P29/00 , C07D213/74 , C07D213/80 , C07D213/85 , C07D401/04 , C07D401/14 , C07D405/12 , A61K31/496
CPC分类号: C07D213/74 , C07D213/80 , C07D213/85 , C07D401/04 , C07D401/14 , C07D405/12
摘要: A compound of formula (wherein A, R1, R2, R6, m and n are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Piperazine Compound”); pharmaceutical compositions comprising a Piperazine Compound; and methods for treating pain, urinary incontinence (UI), an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis (ALS), dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia and depression in an animal comprising administering to an animal in need thereof an effective amount of a Piperazine Compound are disclosed.
摘要翻译: 式(其中A,R 1,R 2,R 6,m和n在本文中公开)的化合物或其药学上可接受的盐(“哌嗪化合物”); 包含哌嗪化合物的药物组合物; 和治疗疼痛,尿失禁(UI),成瘾性障碍,帕金森病,帕金森综合征,焦虑症,癫痫,中风,癫痫发作,瘙痒症状,精神病,认知障碍,记忆缺陷,限制性脑功能,亨廷顿氏舞蹈症 ,肌萎缩性侧索硬化(ALS),痴呆,视网膜病变,肌肉痉挛,偏头痛,呕吐,运动障碍和抑郁症,包括向有需要的动物施用有效量的哌嗪化合物。
-
-
-
-
-
-
-
-
-